At baseline and after @ week of therapy , fecal microbiota composition ( Human Intestinal Tract Chip phylogenetic microarray ) , fecal and plasma bile acid concentrations as well as insulin sensitivity ( hyperinsulinemic euglycemic clamp using -LSB- @,@ - ( @ ) H@ -RSB- - glucose tracer ) were measured .